Oragenics, Inc.
OGEN, a leader in the development of novel, effective antibiotics
and oral care probiotics, and Intrexon Corporation XON, a leader in
synthetic biology, today announced the establishment of an Exclusive Channel
Collaboration (ECC) to develop and commercialize genetically modified
probiotics for the treatment of diseases of the oral cavity, throat, sinus and
esophagus. The team is expected to initially focus on therapies for Behcet's
disease and aphthous stomatitis.
The collaborators will utilize their technical and clinical expertise with
genetically modified oral microbes to pursue a novel, short-term therapeutic
agent. The ECC plans to design genetically modified probiotics that will work
orally, administered in, for example, lozenge form rather than through the
digestive system – thereby increasing the probability of effective treatment
outcomes.
It is anticipated that the therapeutic will treat oral lesions associated with
Behcet's, targeting pain management and functional impairment by suppressing
the inflammatory response, reducing frequency of occurrence and avoiding the
onset of new lesions. The same treatment may also be applicable in the more
commonly experienced recurrent aphthuous stomatitis, better known as canker
sores. Both disease states are currently only treated symptomatically and with
limited success.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in